Cargando…
IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing
Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, in 2017, IQN Path provided external quality assessment for liquid biopsy...
Autores principales: | Deans, Zandra C., Butler, Rachel, Cheetham, Melanie, Dequeker, Elisabeth M. C., Fairley, Jennifer A., Fenizia, Francesca, Hall, Jacqueline A., Keppens, Cleo, Normanno, Nicola, Schuuring, Ed, Patton, Simon J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581928/ https://www.ncbi.nlm.nih.gov/pubmed/31028539 http://dx.doi.org/10.1007/s00428-019-02571-3 |
Ejemplares similares
-
Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
por: Deans, Zandra C., et al.
Publicado: (2017) -
Results of a worldwide external quality assessment of cfDNA testing in lung Cancer
por: Fairley, Jennifer A., et al.
Publicado: (2022) -
International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA
por: Keppens, Cleo, et al.
Publicado: (2018) -
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
por: Deans, Zandra C, et al.
Publicado: (2016) -
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)
por: Fenizia, Francesca, et al.
Publicado: (2021)